Fig. 4
From: RNA editing in cancer impacts mRNA abundance in immune response pathways
ADAR1 or ADAR2 knockdown induced EMT. a Images of A549 cells transfected with siRNAs for ADAR1 knockdown (KD) (siADAR1) or control siRNAs (siControl). Scale bars, 100 μm. b Loss of epithelial markers (E-cadherin and γ-Catenin) and induction of mesenchymal marker (Vimentin) in A549 cells upon ADAR1 KD. Cells were treated with 100 nM siRNA for 72 h. Three biological replicates were used in each condition. c Images of A549 cells transfected with siRNAs for ADAR2 KD (siADAR2) or control siRNAs (siControl). Scale bars, 100 μm. d Loss of epithelial markers (E-cadherin and γ-Catenin) and induction of mesenchymal marker (Vimentin) in A549 cells upon ADAR2 KD. Cells were treated with 11 nM siRNA for 72 h. Three biological replicates were used in each condition. e Images of MCF10A cells with ADAR1 or ADAR2 KD or control siRNAs. Scale bars, 100 μm. f Loss of epithelial markers (E-cadherin and γ-Catenin) and induction of mesenchymal markers (Vimentin) in MCF10A cells upon ADAR1 KD or ADAR2 KD. Cells were treated with 11 nM siRNA for 72 h. Three biological replicates were used in each condition